adjunctive therapy

DRUG2 trials

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Novartis

Conditions

NSCLCocular hypertension open-angle glaucoma

Phase 2

Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for Resectable II-IIIB NSCLC

Not yet recruitingNCT07729670

Cancer Institute and Hospital, Chinese Academy of Medical SciencesNSCLC

Start: 2026-06-01End: 2031-06-01Target: 42Updated: 2026-07-27

Phase 4

Safety and Efficacy with Twice Daily Brinzolamide 1% / Brimonidine 0.2% (SIMBRINZA) as an Adjunctive Therapy to Travoprost 0.004% / Timolol 0.5% (DUOTRAV)

Active, not recruitingNL-OMON46879

Novartisocular hypertension open-angle glaucoma

Start: 2016-06-24Target: 6Updated: 2024-02-28